Mekinist

Generic name: trametinib

Used for: Melanoma with a BRAF mutation · Non-small cell lung cancer with a BRAF mutation · Anaplastic thyroid cancer with a BRAF mutation · Other solid tumors with a BRAF mutation · Low-grade glioma with a BRAF mutation · 4 more

How do you pay?

How to pay the least

Ask for the cash price

Mekinist

We didn’t find one.

  1. Ask your pharmacy for Mekinist’s cash price, and one or two other pharmacies too.
  2. Mekinist’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify 

Compare every option

Question
Brand nameMekinist
Authorized generictrametinib
Regular generictrametinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Mekinist?
The original
–
–

Brand nameThe maker’s card

Novartis Oncology Universal Co-pay Program

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

The card takes up to $15,000 a year off your co-pay.

Sign up on us.tafinlarmekinist.com 

Or call 1-877-577-7756.

In the maker’s words

“Eligible patients with private insurance may pay $0 per month ($0 per month for a 30-day supply of TAFINLAR and $0 for a 30-day supply of MEKINIST).”

From the maker’s offer on us.tafinlarmekinist.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Mekinist itself, from the same company, sold without the brand name, and usually for less. For now Mekinist is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.

MEKINIST is indicated, in combination with dabrafenib, for:

  • the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
  • the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
  • the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
  • the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.
  • the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
  • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.

Limitations of Use: MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.

Source: the FDA label for Mekinist (Novartis Pharmaceuticals Corporation), May 7, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/mekinist/